公开(公告)号：US11498946B2

公开(公告)日：2022-11-15

申请号：US17118767

申请日：2020-12-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Hong Yeol Yoon ,  Man Kyu Shim ,  Suah Yang

IPC: C07K14/47 ,  A61P35/00 ,  A61K47/10 ,  C07K16/28 ,  A61K47/64

Abstract: The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues.
In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

公开(公告)号：US11833204B2

公开(公告)日：2023-12-05

申请号：US17529450

申请日：2021-11-18

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  In-Cheol Sun ,  Man Kyu Shim ,  Ji Woong Choi

IPC: A61K31/351 ,  A61K41/00 ,  A61P35/00 ,  A61K47/69

CPC classification number: A61K41/0076 ,  A61K31/351 ,  A61K47/6929 ,  A61P35/00

Abstract: Disclosed are visible light-activatable antitumor self-assembled nanoparticles or antitumor immunity-inducing self-assembled nanoparticles. The self-assembled nanoparticles induce potent apoptosis in cancer cells and increase their own anticancer immunogenicity, thereby maximizing their therapeutic efficacy for cancer.

公开(公告)号：US10213515B2

公开(公告)日：2019-02-26

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Ick Chan Kwon ,  Man Kyu Shim ,  Hong Yeol Yoon

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00 ,  C07K9/00 ,  G01N33/574 ,  G01N33/58 ,  C07K5/11 ,  C07K5/107 ,  A61K47/54

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.